abituzumab
Abituzumab is a humanized IgG2 monoclonal antibody (mAb) targeted at CD51 currently in development by Merck KGaA Darmstadt, Germany in an attempt to prevent bone lesion metastases in castration-resistant prostate cancer. — Wikipedia
Clinical trial activity
6 trials · 3 clinical orgs · 0 marketing orgs
Earliest trial started Oct 1, 2008 (NCT00958477)
Timeline
Indications
Mechanism of action
- Integrin alpha-V/beta-3INHIBITOR
Integrin alpha-V/beta-3 inhibitor
Inhibits ligand binding to all alphav heterodimers (alphavbeta1, alphavbeta3, alphavbeta5, alphavbeta6, alphavbeta8).
Specifically directed against the alphaV subunit of human integrins.
- Integrin alpha-V/beta-5INHIBITOR
Integrin alpha-V/beta-5 inhibitor
Inhibits ligand binding to all alphav heterodimers (alphavbeta1, alphavbeta3, alphavbeta5, alphavbeta6, alphavbeta8).
Specifically directed against the alphav subunit of human integrins.
- Integrin alpha-V/beta-6INHIBITOR
Integrin alpha-V/beta-6 inhibitor
Inhibits ligand binding to all alphav heterodimers (alphavbeta1, alphavbeta3, alphavbeta5, alphavbeta6, alphavbeta8).
Specifically directed against the alphav subunit of human integrins.
- Integrin alpha-V/beta-1INHIBITOR
Integrin alpha-V/beta-1 inhibitor
Inhibits ligand binding to all alphav heterodimers (alphavbeta1, alphavbeta3, alphavbeta5, alphavbeta6, alphavbeta8).
Specifically directed against the alphaV subunit of human integrins.
- Integrin alpha-V/betaINHIBITOR
Integrin alpha-V/beta-8 inhibitor
Inhibits ligand binding to all alphav heterodimers (alphavbeta1, alphavbeta3, alphavbeta5, alphavbeta6, alphavbeta8).
Specifically directed against the alphav subunit of human integrins.
- Vitronectin receptor alphaINHIBITOR
ITGAV inhibitor
Inhibits ligand binding to all alphav heterodimers (alphavbeta1, alphavbeta3, alphavbeta5, alphavbeta6, alphavbeta8).
Specifically directed against the alphav subunit of human integrins.
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaAbituzumab ↗
- ChEMBLCHEMBL2109621 ↗
Also known as
- abituzumab
- abituzumab
- abituzumab
- ald403
- di17e6
- di17e6
- emd525797
- emd 525797
- emd 525797
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02745145 | Phase 2 | Apr 30, 2016 | Merck KGaA, Merck Serono |
| NCT01360840 | Phase 2 | Apr 1, 2011 | Merck Serono |
| NCT01327313 | Phase 1 | Jan 1, 2011 | Merck KGaA, Merck Serono |
| NCT01008475 | Phase 1/Phase 2 (Phase 2) | Oct 1, 2009 | Merck KGaA, Universidad Autonoma de Barcelona |
| NCT00848510 | Phase 1 | Feb 1, 2009 | Merck KGaA |
| NCT00958477 | Phase 1 | Oct 1, 2008 | Merck KGaA |
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Merck KGaA | For profit | 5 | 4 | 2 | 2008 |
| Merck Serono | For profit | 3 | 2 | 2 | 2011 |
| Universidad Autonoma de Barcelona | Academic/Hospital | 1 | 0 | 1 | 2009 |